Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03354728 · ClinicalTrials.gov registry record · Phase 1
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
A Phase 1 study of Cytomegaloviral Infection and Hematopoietic Cell Transplant Recipient, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT03354728: Recruiting Phase 1 study of Cytomegaloviral Infection and Hematopoietic Cell Transplant Recipient, sponsored by City of Hope Medical Center.
NCT03354728 is a Phase 1 study of Cytomegaloviral Infection and Hematopoietic Cell Transplant Recipient that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 80 participants, above the 60-participant average among 3 other Cytomegaloviral Infection trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03354728, a Phase 1 study of Cytomegaloviral Infection and Hematopoietic Cell Transplant Recipient, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who are undergoing donor stem cell transplant. Multi-antigen CMV-modified vaccinia ankara vaccine may help people resist CMV life-threatening complications.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-05-11 |
| Est. Completion | 2026-12-11 |
| Phase | Phase 1 |
What NCT03354728 shows while recruiting
NCT03354728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 3 other Cytomegaloviral Infection trials with a reported enrollment target (33% higher).
The record links to 2 conditions, with Cytomegaloviral Infection appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03354728 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03354728 about?
NCT03354728 is a clinical study titled "Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant". This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who are undergoing donor stem cell transplant. Multi-antigen CMV-modified vac...
What is the current status of trial NCT03354728?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2018-05-11. Estimated completion is 2026-12-11.
What conditions does trial NCT03354728 study?
This clinical trial studies the following conditions: Cytomegaloviral Infection, Hematopoietic Cell Transplant Recipient.
What interventions are being tested in trial NCT03354728?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Multi-peptide CMV-Modified Vaccinia Ankara Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03354728?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03354728 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegaloviral Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
RECRUITING · Phase 1
-
Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection
ACTIVE NOT RECRUITING · Phase 2
-
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI